Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal A, C, Y, W tetanus toxoid conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal A, C, Y, W tetanus toxoid conjugate vaccine is a **quadrivalent conjugate vaccine** designed to prevent invasive disease caused by *Neisseria meningitidis* serogroups **A, C, W, and Y**[1][2][4][5]. The vaccine contains polysaccharides from each targeted serogroup conjugated to **tetanus toxoid** protein, serving as a carrier to enhance immunogenicity and establish long-term immunity[1][2]. When administered, the vaccine stimulates antibody production against the polysaccharide capsules of the relevant serogroups, conferring bactericidal immune protection[1][4]. It is approved for active immunization of individuals 12 months and older in Europe and 2 years and older in the USA, available as a single-dose liquid or powder for suspension[1][2][4][5].
- Brand names
- MenQuadfiNimenrix
- Other names
- meningococcal conjugate quadrivalentMenACWY-TTmeningococcal polysaccharide (groups A, C, Y, W-135) tetanus toxoid conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideGroup Y CPS (Neisseria meningitidis group Y capsular polysaccharide)TT (Tetanus toxoid)
Beyond the preview
Go deeper on meningococcal A, C, Y, W tetanus toxoid conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal A, C, Y, W tetanus toxoid conjugate vaccine.